Compare ATGL & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATGL | BCYC |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | Hong Kong | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.9M | 476.6M |
| IPO Year | 2023 | 2019 |
| Metric | ATGL | BCYC |
|---|---|---|
| Price | $20.15 | $7.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $18.73 |
| AVG Volume (30 Days) | 39.2K | ★ 237.4K |
| Earning Date | 01-27-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,206,460.00 | ★ $28,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.36 | N/A |
| 52 Week Low | $9.01 | $6.03 |
| 52 Week High | $57.32 | $13.66 |
| Indicator | ATGL | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 41.53 | 53.61 |
| Support Level | $18.30 | $6.37 |
| Resistance Level | $22.10 | $7.34 |
| Average True Range (ATR) | 4.30 | 0.33 |
| MACD | -0.56 | 0.06 |
| Stochastic Oscillator | 2.21 | 67.31 |
Alpha Technology Group Ltd operates through its subsidiaries, which are established cloud-based IT solution service providers in Hong Kong. Its Operating Subsidiaries utilize its analytic skills, programming skills, artificial intelligence technologies and technological know-how to provide comprehensive solutions designed to optimize the business performance of customers, meet various industry-specific operational challenges of customers and create new business opportunities for customers. The Operating Subsidiaries provide services for customers from a variety of industries, including consulting, real estate, architectural design, carpark management, electronic payment services, logistics, investments, retail, textiles, wholesale and distribution, etc.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.